{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T03:08:15Z","timestamp":1778468895615,"version":"3.51.4"},"posted":{"date-parts":[[2026,2,11]]},"group-title":"In Review","reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,1,24]]},"abstract":"<title>Abstract<\/title>\n                <p>Background\n Immune checkpoint inhibitors can result in serious, long-lasting immune-related adverse events (irAEs). Early identification of symptoms predictive of irAEs could enhance monitoring and timely intervention. This study assessed whether symptoms within the first 8 weeks of treatment could predict subsequent development of immune-related adrenal insufficiency(AI) or hypothyroidism.\nMethods\n This retrospective cohort study analyzed prospectively collected data from the I-SPY2 trial, a phase 2 platform trial for high-risk stage II\/III breast cancer across 30 U.S. sites. The cohort included 482 women treated with experimental immunotherapy agents concurrent with weekly paclitaxel neoadjuvant chemotherapy. The primary outcomes were grade\u2009\u2265\u20091 hypothyroidism or AI, adjudicated by an independent safety group, up to 1-year post-treatment. Symptoms and irAEs were assessed using the Common Terminology Criteria for Adverse Events. Symptom burden was quantified as area under the curve (AUC) based on symptom grade and duration. Predictive modeling was performed using logistic regression and ROC analysis; symptom enrichment between cases and controls was evaluated using Fisher\u2019s exact tests.\nResults\n Among 482 participants, 107 (22.2%) developed irAEs, with hypothyroidism (n\u2009=\u200961, 12.7%) occurring more frequently than AI (n\u2009=\u200938, 7.9%) at medians of 99 and 105 days from treatment initiation, respectively. Symptom enrichment analysis identified early predictive symptoms. Fatigue (17.2% vs 6.8%, p\u2009=\u20090.011) and rash (20.7% vs 7.8%, p\u2009=\u20090.0037) were predictive of hypothyroidism, while diarrhea (45.9% vs 31%, p\u2009=\u20090.048), constipation (5.4% vs 0.2%, p\u2009=\u20090.018), and taste changes (5.4% vs 0.5%, p\u2009=\u20090.034) were associated with AI. A predictive model demonstrated moderate performance (AUC 0.65 for AI, p\u2009&lt;\u20090.0001; AUC 0.61 for hypothyroidism, p\u2009=\u20090.012). Model accuracy in an external validation cohort was 72.8% for AI and 74.7% for hypothyroidism.\nConclusions\n This study presents a predictive framework to identify patients at risk for adrenal insufficiency and hypothyroidism as irAEs, enabling personalized care and proactive intervention to improve treatment outcomes and safety.<\/p>","DOI":"10.21203\/rs.3.rs-8689063\/v1","type":"posted-content","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:39:46Z","timestamp":1770788386000},"source":"Crossref","is-referenced-by-count":0,"title":["Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial"],"prefix":"10.21203","author":[{"given":"Amrita","family":"Basu","sequence":"first","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saumya","family":"Umashankar","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Melisko","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritu","family":"Roy","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Yau","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[{"name":"Yale University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Jo","family":"Chien","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minetta","family":"Liu","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo","family":"Han","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatem","family":"Soliman","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudine","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Georgetown University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Shatsky","sequence":"additional","affiliation":[{"name":"University of California, San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Stringer-Reasor","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Robinson","sequence":"additional","affiliation":[{"name":"Loyola University Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Yeung","sequence":"additional","affiliation":[{"name":"University of California, San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Kalinsky","sequence":"additional","affiliation":[{"name":"Emory University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Thomas","sequence":"additional","affiliation":[{"name":"Wake Forest University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Errol","family":"Philip","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Musthafa","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Hirst","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Asare","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"DeMichele","sequence":"additional","affiliation":[{"name":"University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura van't","family":"Veer","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Yee","sequence":"additional","affiliation":[{"name":"University of Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nola","family":"Hylton","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Olshen","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Perlmutter","sequence":"additional","affiliation":[{"name":"Gemini Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Cohen","sequence":"additional","affiliation":[{"name":"University of Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Quandt","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Esserman","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Hershman","sequence":"additional","affiliation":[{"name":"Columbia University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hope","family":"Rugo","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Nanda","sequence":"additional","affiliation":[{"name":"University of Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","author":"Esfahani K","year":"2020","unstructured":"Esfahani, K., et al., A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol, 2020. 27(Suppl 2): p. S87-s97."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.breast.2017.05.013","article-title":"The emerging world of breast cancer immunotherapy","volume":"37","author":"Nathan MR","year":"2018","unstructured":"Nathan, M.R. and P. Schmid, The emerging world of breast cancer immunotherapy. Breast, 2018. 37: p. 200\u2013206.","journal-title":"Breast"},{"issue":"10265","key":"ref3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes J","year":"2020","unstructured":"Cortes, J., et al., Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet, 2020. 396(10265): p. 1817\u20131828.","journal-title":"Lancet"},{"issue":"18","key":"ref4","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2217\/fon-2021-1647","article-title":"KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer","volume":"18","author":"Rizzo A","year":"2022","unstructured":"Rizzo, A., et al., KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. Future Oncol, 2022. 18(18): p. 2301\u20132309.","journal-title":"Future Oncol"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid P","year":"2020","unstructured":"Schmid, P., et al., Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med, 2020. 382(9): p. 810\u2013821.","journal-title":"N Engl J Med"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9111687","article-title":"Immunotherapy in Breast Cancer: When, How, and What Challenges?","volume":"9","author":"Henriques B","year":"2021","unstructured":"Henriques, B., F. Mendes, and D. Martins, Immunotherapy in Breast Cancer: When, How, and What Challenges? Biomedicines, 2021. 9(11).","journal-title":"Biomedicines"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"173867","DOI":"10.1016\/j.ejphar.2021.173867","article-title":"The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy","volume":"895","author":"Setordzi P","year":"2021","unstructured":"Setordzi, P., et al., The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. Eur J Pharmacol, 2021. 895: p. 173867.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"ref8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","article-title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: Results from the adaptively randomized I-SPY2 trial","volume":"39","author":"Pusztai L","year":"2021","unstructured":"Pusztai, L., et al., Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell, 2021. 39(7): p. 989\u2013998 e5.","journal-title":"Cancer Cell"},{"key":"ref9","volume-title":"LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo\u2009+\u2009endocrine therapy (ET) for early-stage high-risk ER+\/HER2\u2013 breast cancer","author":"Cardoso F","unstructured":"Cardoso F, M.H., Schmid P, et al, LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo\u2009+\u2009endocrine therapy (ET) for early-stage high-risk ER+\/HER2\u2013 breast cancer. Annals of Oncology."},{"key":"ref10","volume-title":"LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) \u00b1 NIVO in patients (pts) with high-risk, ER+ HER2\u2009\u2013\u2009primary breast cancer (BC)","author":"Loi S","unstructured":"Loi S, C.G., Salgado RF, et al, LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) \u00b1 NIVO in patients (pts) with high-risk, ER+ HER2\u2009\u2013\u2009primary breast cancer (BC). Annals of Oncology."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"103354","DOI":"10.1016\/j.critrevonc.2021.103354","article-title":"Managing side effects of immune checkpoint inhibitors in breast cancer","volume":"162","author":"Criscitiello C","year":"2021","unstructured":"Criscitiello, C., et al., Managing side effects of immune checkpoint inhibitors in breast cancer. Crit Rev Oncol Hematol, 2021. 162: p. 103354.","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"657634","DOI":"10.3389\/fonc.2021.657634","article-title":"Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials","volume":"11","author":"Li Y","year":"2021","unstructured":"Li, Y., et al., Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Front Oncol, 2021. 11: p. 657634.","journal-title":"Front Oncol"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1007\/s00432-021-03591-w","article-title":"Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis","volume":"147","author":"Sternschuss M","year":"2021","unstructured":"Sternschuss, M., et al., Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol, 2021. 147(11): p. 3369\u20133379.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1186\/s12885-021-08997-w","article-title":"Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis","volume":"21","author":"Xin Y","year":"2021","unstructured":"Xin, Y., et al., Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer, 2021. 21(1): p. 1261.","journal-title":"BMC Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"107796","DOI":"10.1016\/j.intimp.2021.107796","article-title":"Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis","volume":"96","author":"Balibegloo M","year":"2021","unstructured":"Balibegloo, M., et al., Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis. Int Immunopharmacol, 2021. 96: p. 107796.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial","volume":"6","author":"Nanda R","year":"2020","unstructured":"Nanda, R., et al., Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol, 2020. 6(5): p. 676\u2013684.","journal-title":"JAMA Oncol"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.21037\/atm-21-7006","article-title":"Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study","volume":"10","author":"Cui K","year":"2022","unstructured":"Cui, K., et al., Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study. Ann Transl Med, 2022. 10(5): p. 251.","journal-title":"Ann Transl Med"},{"issue":"8","key":"ref18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis","volume":"25","author":"Grouthier V","year":"2020","unstructured":"Grouthier, V., et al., Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. Oncologist, 2020. 25(8): p. 696\u2013701.","journal-title":"Oncologist"},{"issue":"7","key":"ref19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41571-019-0216-2","article-title":"Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?","volume":"16","author":"D'Abreo N","year":"2019","unstructured":"D'Abreo, N. and S. Adams, Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first? Nat Rev Clin Oncol, 2019. 16(7): p. 399\u2013400.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12609-019-00334-2","article-title":"I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer","volume":"11","author":"Wang H","year":"2019","unstructured":"Wang, H. and D. Yee, I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer. Curr Breast Cancer Rep, 2019. 11(4): p. 303\u2013310.","journal-title":"Curr Breast Cancer Rep"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan S","year":"2019","unstructured":"Khan, S., et al., Immune dysregulation in cancer patients developing immune-related adverse events. Br J Cancer, 2019. 120(1): p. 63\u201368.","journal-title":"Br J Cancer"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors","volume":"13","author":"Chennamadhavuni A","year":"2022","unstructured":"Chennamadhavuni, A., et al., Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. Front Immunol, 2022. 13: p. 779691.","journal-title":"Front Immunol"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41525-022-00345-6","article-title":"Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity","volume":"7","author":"Chin IS","year":"2022","unstructured":"Chin, I.S., et al., Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity. NPJ Genom Med, 2022. 7(1): p. 73.","journal-title":"NPJ Genom Med"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy","volume":"11","author":"Jing Y","year":"2020","unstructured":"Jing, Y., et al., Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun, 2020. 11(1): p. 4946.","journal-title":"Nat Commun"},{"issue":"5","key":"ref25","article-title":"Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events","volume":"15","author":"Les I","year":"2023","unstructured":"Les, I., et al., Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. Cancers (Basel), 2023. 15(5).","journal-title":"Cancers (Basel)"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jamia\/ocae190","article-title":"Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer","volume":"32","author":"Northrop A","year":"2025","unstructured":"Northrop, A., et al., Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer. J Am Med Inform Assoc, 2025. 32(1): p. 172\u2013180.","journal-title":"J Am Med Inform Assoc"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8689063\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8689063\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T02:11:55Z","timestamp":1778465515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8689063\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":26,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-8689063\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,2,11]]},"subtype":"preprint"}}